Compounded semaglutide
Sold by Actin · Injection · device not recorded · every compounded semaglutide record
The program identifies an injection, but the delivery device has not been established.
Price
| Term | Published rate | Charged today |
|---|---|---|
| Standard semaglutide — 1-month selection, advertised $169; payment interval unverified Price conditions have not been established; the quoted figure is not a verified recurring rate. Prescription and individual/state eligibility required. This is an advertised figure, not a verified charge today or recurring invoice; plan labels and delivery descriptions do not establish a calendar-month payment interval. Advertised“Most Flexible 1-Month $169” | $169Published figure | Charged todayNot verified |
| Microdose semaglutide — 1-month selection, advertised $149; payment interval unverified Price conditions have not been established; the quoted figure is not a verified recurring rate. Prescription and individual/state eligibility required. This is an advertised figure, not a verified charge today or recurring invoice; plan labels and delivery descriptions do not establish a calendar-month payment interval. Advertised“Most Flexible 1-Month $149” | $149Published figure | Charged todayNot verified |
| Standard semaglutide — 3-month selection, advertised $143; payment interval unverified Price conditions have not been established; the quoted figure is not a verified recurring rate. Prescription and individual/state eligibility required. This is an advertised figure, not a verified charge today or recurring invoice; plan labels and delivery descriptions do not establish a calendar-month payment interval. Advertised“Most Popular 3-Month $143” | $143Published figure | Charged todayNot verified |
| Microdose semaglutide — 3-month selection, advertised $133; payment interval unverified Price conditions have not been established; the quoted figure is not a verified recurring rate. Prescription and individual/state eligibility required. This is an advertised figure, not a verified charge today or recurring invoice; plan labels and delivery descriptions do not establish a calendar-month payment interval. Advertised“Best Value 3-Month $133” | $133Published figure | Charged todayNot verified |
| Standard semaglutide — 6-month selection, advertised $116; payment interval unverified Price conditions have not been established; the quoted figure is not a verified recurring rate. Prescription and individual/state eligibility required. This is an advertised figure, not a verified charge today or recurring invoice; plan labels and delivery descriptions do not establish a calendar-month payment interval. Advertised“Best Value 6-Month $116” | $116Published figure | Charged todayNot verified |
Price sources
- Standard semaglutide — 1-month selection, advertised $169; payment interval unverified · actin.com — read October 2026
- Microdose semaglutide — 1-month selection, advertised $149; payment interval unverified · actin.com — read October 2026
- Standard semaglutide — 3-month selection, advertised $143; payment interval unverified · actin.com — read October 2026
- Microdose semaglutide — 3-month selection, advertised $133; payment interval unverified · actin.com — read October 2026
- Standard semaglutide — 6-month selection, advertised $116; payment interval unverified · actin.com — read October 2026
We earn nothing from this link. It opens Actin's website without a paid referral.
History
Fewer than two comparable calendar-month readings are available for a price trend. Day- or week-based supplies, introductory offers and unverified payment terms are not connected in this chart.
- September 2026 — Entry added to the register
Sourcing and terms
| Pharmacy | Not disclosed |
|---|---|
| States | Not disclosed |
| Prescriber | Not disclosed |
| Cancellation | Subscriptions may renew automatically at checkout-defined intervals. Cancellation through the account or support takes effect after the current subscription period. The terms describe sales and subscription fees as final/nonrefundable while reserving case-by-case remedies. |
| Membership | None. “No hidden fees or membership required” |
| Consult fee | Not disclosed |
Recorded from actin.com. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.
Notes
- 1. September 2026 — Homepage badge literally reads 'No Membership Fees' and both product pages say 'Same price, forever' and 'No hidden fees or membership required' — the per-month figures already include the medication, this is not the membership trap. Per-month prices for the 3/6-month plans are the only figures printed; no separate upfront total was shown, so upfront was recorded equal to perMonth rather than computed. Device form (vial vs. pen) is never stated for either drug.
- 2. October 2026 — Actin Telehealth, Inc. operates the platform and says it is not a healthcare provider. The public footer names Beluga Health, P.A. for medical services; no individual treating clinician or independent credential verification is established. Source: https://actin.com/page/terms-of-service.
- 3. October 2026 — The public footer lists The Pharmacy Hub, GreenwichRX and Hallandale Pharmacy. This is a disclosed partner network, not confirmation of the pharmacy assigned to this program. Product pictures are explicitly illustrative. Source: https://actin.com/.
- 4. October 2026 — No membership fee is advertised. The products include clinician support, dose adjustments, wipes, syringes and delivery. The terms describe a single subscription total that can include provider and pharmacy charges; no separate universally required consultation amount is established in the reviewed public pages. Source: https://actin.com/lose-weight/compounded-semaglutide.
- 5. October 2026 — The terms describe cash-pay services and say the practices do not accept commercial health insurance or Medicare/Medicaid. HSA/FSA and financing badges do not establish insurance coverage. Source: https://actin.com/page/terms-of-service.
- 6. October 2026 — Services are limited to eligible U.S. locations, and some services are available only in certain states. The reviewed public pages do not establish a complete treatment-specific state roster. No current lab requirement or included lab price is established. Source: https://actin.com/page/terms-of-service.
- 7. October 2026 — The public process describes clinician review of submitted information and continuing in-app messaging. A mandatory live-visit requirement is not established on the reviewed pages. The linked support FAQ returned a security-verification page and was not bypassed. Source: https://actin.com/.
- 8. October 2026 — Subscriptions can renew automatically at intervals described during checkout. Cancellation through the account or support takes effect after the current subscription period. The terms describe sales and subscription fees as final/nonrefundable, while reserving case-by-case remedies. Confirm the final invoice and renewal terms before purchase. Source: https://actin.com/page/terms-of-service.
- 9. October 2026 — Product pages advertise free delivery, and the terms say delivery estimates are not guaranteed and any applicable shipping charges appear before purchase. The actual order total and renewal charge remain unverified. Source: https://actin.com/page/terms-of-service.
- 10. October 2026 — The general GLP-1 landing page repeats the semaglutide and tirzepatide starting figures and advertises $50 off a first order. The offer does not establish which plan qualifies or a discounted recurring price, so no subtraction or extra ingredient record is inferred. Source: https://actin.com/lose-weight/compounded-glp1.
- 11. October 2026 — The microdose product explicitly names semaglutide with vitamin B12 and once-weekly subcutaneous injections. It is retained as a lower-dose variant, not a second ingredient identity. The page inconsistently describes intended BMI as under 27 in one area and under 25 in another; clinician eligibility is not inferred from either claim. Source: https://actin.com/live-longer/glp1-microdose.
1 further note concerns other Actin programs and sit on the provider record.
Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.